Trials / Completed
CompletedNCT06549816
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
An Open-label, Phase 1 Study to Investigate the Safety and Pharmacokinetics of SGN-B6A in Chinese Subjects With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) to find out whether it is safe for Chinese participants who have solid tumors. It will study sigvotatug vedotin to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study how do Chinese participants' body interact with sigvotatug vedotin.
Conditions
- Carcinoma, Non-Small Cell Lung
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Esophageal Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | sigvotatug vedotin | Sigvotatug vedotin is a antibody-drug conjugate (ADC) designed to deliver the cytotoxic agent monomethyl auristatin E (MMAE) to cells expressing integrin beta-6. |
Timeline
- Start date
- 2024-08-21
- Primary completion
- 2025-11-18
- Completion
- 2025-11-18
- First posted
- 2024-08-12
- Last updated
- 2025-12-15
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06549816. Inclusion in this directory is not an endorsement.